

Firocoxib

Catalog No: tcsc3419



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

189954-96-9

Formula:

$C_{17}H_{20}O_5S$

Pathway:

Immunology/Inflammation

Target:

COX

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 52 mg/mL (154.58 mM)

Alternative Names:

ML 1785713

Observed Molecular Weight:

336.4

Product Description


Firocoxib(ML 1785713) is a potent and selective cyclooxygenase (COX)-2 inhibitor with IC₅₀ of 0.13 μ M, 58 fold sensitivity for COX2 VSCOX1.

IC₅₀ value: 0.13 μ M [1]

Target: COX2 inhibitor

in vitro: Blood concentrations resulting in 50% inhibition of COX-1 and COX-2 activity in vitro were 75 \pm 2 μ M and 0.13 \pm 0.03 μ M, respectively, and selectivity for inhibiting COX-2 relative to COX-1 was 58. Firocoxib had moderate to high oral bioavailability (54% to 70%), low plasma clearance (4.7 to 5.8 mL/min/kg), and an elimination half-life of 8.7 to 12.2 hours [1].

in vivo: Administration of firocoxib did not cause any adverse effects on GI, or hematological or serum biochemical variables and appears to have been well tolerated by dogs [2]. Firocoxib (0.5 mg/kg) was initially administered i.v. to calves, and following a 14-day washout period, animals received firocoxib orally prior to cautery dehorning. Firocoxib concentrations were determined by liquid chromatography-tandem mass spectrometry [3]. Firocoxib 5 mg/kg was given orally once daily for 180 days to five dogs with clinical signs and histopathological lesions consistent with solar dermatitis/actinic keratosis. On days 0, 50 and 180, the severity of erythema, skin shine, induration and the number of comedones were evaluated by a clinical scoring system [4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!